ZOLL Cardiac Management Solutions

BREAKING: An expert consensus on early SCD risk in HFrEF patients has published in the Journal of Cardiac Failure (@JCardFail).

The authors assessed contemporary evidence on SCD incidence in the modern era of GDMT including a review of the SCD-PROTECT (2025) study of nearly 20,000 consecutive LifeVest® WCD patients. One important finding: there’s a clear distinction between early and chronic SCD risk.

Read the publication: onlinejcf.com/article/S1071-…

Reducing heart failure readmissions with earlier patient intervention.

ZOLL Heart Failure Management System (HFMS) enables care teams to detect pulmonary fluid accumulation before symptoms develop, which helps clinicians act sooner and keep patients out of the hospital.

For Carolyn, that meant:
✔️ Zero hospital visits for heart failure
✔️ Greater peace of mind
✔️ A return to everyday life

Hear directly from Carolyn about her experience and from her prescriber, Chelsea Christensen, PA-C, on how HFMS is changing outcomes in her practice.

▶️ Watch the video below.

Learn more about this real-world evidence: cardiac.zoll.com/medical-profes…

When early SCD risk is high, LifeVest delivers 23.4+ hours/day median compliance,¹⁻³ proven safety,¹ and proven efficacy.⁴⁻⁶

At #HFSA2026, ZOLL will highlight the latest SCD research, including SCD-PROTECT. Despite high utilization of 4-pillar GDMT, there were high LifeVest treatment rates across 19,500+ consecutive patients (NICM and MI/CAD), confirming the importance of early protection.1

Visit us in Booth 321 or review the latest research: cardiac.zoll.com/medical-profes…

1 David Duncker, Eloi Marijon, Marco Metra, Olivier Piot, Marat Fudim, Uwe Siebert, Norbert Frey, Lars Siegfried Maier, Johann Bauersachs, Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study, European Heart Journal, 2025;, ehaf668, doi.org/10.1093/eurhea…;
2 Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. EP Europace. 2020;23(1):73-81. doi:10.1093/europace/euaa268;
3 Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis.
4 Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation. 2015;132(17):1613–1619.
5 Data on file, 90d0241_a01. Report of AArD Performance during 2019.
6 Chung MK, Szykiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, & Tchou PJ (2010). Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. Journal of the American College of Cardiology, 56(3), 194–203.

Attending the HFSA Annual Scientific Meeting in Phoenix this weekend?

Make plans to join ZOLL's Industry Expert Theater session: "Why is it time to rethink early SCD risk in HF?"

Connect with experts Adam DeVore, MD, MHS and Ben D'Souza, MD, FACC, FHRS, for a discussion on early sudden cardiac death risk in heart failure and what it may mean for patient care.

📅 Saturday, October 10
⏰ 8 a.m. - 8:45 a.m. MST
📍 Exhibit Hall, Theater 1

Add it to your schedule today.

#HFSA2026 #HeartFailureScience #Cardiology

Heart failure management continues to evolve, and we're excited to be part of the conversation at the upcoming HFSA Annual Scientific Meeting.

Don't miss Dr. Ahmad Barbour's poster presentation on new research evaluating the impact of inpatient initiation of ZOLL HFMS on heart failure readmissions.

📝 "Impact of Inpatient Initiation of Wearable Radiofrequency Thoracic Fluid Monitoring (ZOLL HFMS) on Heart Failure Readmissions: A Prospective Single-Center Study"
📅 Saturday, October 10 | 8:15 - 8:45 a.m.
📍 Oral Abstract Sessions, Monitor 1

Mark the session on your agenda, then visit Booth 321 at hashtag#HFSA2026 to learn more about ZOLL HFMS.